May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Fluoroquinolone Therapy for Experimental LASIK-Associated Staphylococcus Keratitis
Author Affiliations & Notes
  • A. R. Caballero
    Univ of Mississippi Med Ctr, Jackson, Mississippi
    Microbiology,
  • C. L. Balzli
    Univ of Mississippi Med Ctr, Jackson, Mississippi
    Microbiology,
  • C. C. McComrick
    Univ of Mississippi Med Ctr, Jackson, Mississippi
    Microbiology,
  • B. Huang
    Univ of Mississippi Med Ctr, Jackson, Mississippi
    Ophthalmology,
  • L. Wigington
    Univ of Mississippi Med Ctr, Jackson, Mississippi
    Ophthalmology,
  • A. Tang
    Univ of Mississippi Med Ctr, Jackson, Mississippi
    Microbiology,
  • R. J. O'Callaghan
    Univ of Mississippi Med Ctr, Jackson, Mississippi
    Microbiology,
  • Footnotes
    Commercial Relationships A.R. Caballero, Alcon Laboratories, F; C.L. Balzli, None; C.C. McComrick, None; B. Huang, None; L. Wigington, None; A. Tang, None; R.J. O'Callaghan, Alcon Laboratories, F.
  • Footnotes
    Support EY10974
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 2675. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. R. Caballero, C. L. Balzli, C. C. McComrick, B. Huang, L. Wigington, A. Tang, R. J. O'Callaghan; Fluoroquinolone Therapy for Experimental LASIK-Associated Staphylococcus Keratitis. Invest. Ophthalmol. Vis. Sci. 2007;48(13):2675.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To develop, in the rabbit, a unique model of post-LASIK keratitis mediated by Staphylococcus aureus and to determine the effectiveness of ocular fluoroquinolone antibiotics.

Methods:: A corneal flap was created in the rabbit corneas (n = 6 eyes per group) using a microkeratome (Bausch and Lomb Hansatome Excellus). S. aureus strain 91169 (500 CFU, 5 µl), an ulcerative keratitis isolate, was administered under the flap. For prophylactic therapy, a single topical drop of moxifloxacin (0.5%, Vigamox) or gatifloxacin (0.3%, Zymar) was applied at 5 hours before infection and the number of bacteria per cornea was determined 5 hours postinfection (PI). For therapy of active infection, eyes were treated with a single topical drop of antibiotic every hour from 4 to 9 hours PI and the bacterial load determined at 10 hours PI. Corneal homogenates were cultured quantitatively in triplicate; results are expressed as the log CFU ± SEM.

Results:: Bacteria inoculated under the corneal flap grew logarithmically for 10 hours reaching 6.20 ± 0.006 CFU per cornea. Conjunctival chemosis and injection and corneal infiltration and epithelial erosion were observed after 12 hours postinfection. Eyes treated prophylactically with moxifloxacin or gatifloxacin contained 4.76 ± 0.04 or 4.82 ± 0.052 CFU per cornea, respectively, and were significantly lower than the untreated control (P = 0.002 or P = 0.013, respectively). For therapy of infected eyes, eyes treated with moxifloxacin or gatifloxacin contained 1.02 ± 0.145 or 1.18 ± 0.047, respectively, and were significantly lower than the untreated control (P < 0.0001 or P < 0.0001, respectively).

Conclusions:: Infection of the rabbit corneal flap provided a reliable model of keratitis mimicking that following LASIK surgery. Moxifloxacin therapy, relative to gatifloxacin therapy, yielded similar, but numerically superior, bacterial killing following either prophylactic therapy or therapy of active infection.

Keywords: Staphylococcus • keratitis • refractive surgery: LASIK 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×